300 related articles for article (PubMed ID: 21345296)
1. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.
Lubrano E; Spadaro A; Marchesoni A; Olivieri I; Scarpa R; D'Angelo S; Salvarani C; Mathieu A; Cauli A; Ferrara N; Helliwell P
Clin Exp Rheumatol; 2011; 29(1):80-4. PubMed ID: 21345296
[TBL] [Abstract][Full Text] [Related]
2. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
Lubrano E; Parsons WJ; Perrotta FM
J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
Gladman DD; Bombardier C; Thorne C; Haraoui B; Khraishi M; Rahman P; Bensen W; Syrotuik J; Poulin-Costello M
J Rheumatol; 2011 Jul; 38(7):1355-62. PubMed ID: 21572156
[TBL] [Abstract][Full Text] [Related]
5. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
Kirkham B; de Vlam K; Li W; Boggs R; Mallbris L; Nab HW; Tarallo M
Clin Exp Rheumatol; 2015; 33(1):11-9. PubMed ID: 25535650
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
7. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Dunn M; Tsuji W
J Rheumatol; 2006 Apr; 33(4):712-21. PubMed ID: 16463435
[TBL] [Abstract][Full Text] [Related]
8. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
9. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
12. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
13. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.
Scarpa R; Atteno M; Lubrano E; Provenzano G; D'Angelo S; Spadaro A; Costa L; Olivieri I
Clin Rheumatol; 2011 Aug; 30(8):1063-7. PubMed ID: 21360007
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
16. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept.
Mease P
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S116-21. PubMed ID: 12463460
[TBL] [Abstract][Full Text] [Related]
17. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
[TBL] [Abstract][Full Text] [Related]
18. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis.
Yazici Y; Erkan D; Lockshin MD
Clin Exp Rheumatol; 2000; 18(6):732-4. PubMed ID: 11138337
[TBL] [Abstract][Full Text] [Related]
19. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
20. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ
Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]